Richard L. Schilsky, MD
Jennifer Malin, MD
Michael Kolodziej, MD
James C. Robinson
Designed to pay for breakthroughs, the new technology add-on (NTAP) ‘bump’ is also too unpredictable, say drug and device groups.
Childhood cancer hasn’t been a big money maker. A not-for-profit helped fund the research that led to the approval of a new drug for neuroblastoma.
"Arterial kateter (Seldinger)" by Privatarchiv Foto von MrArifnajafov